The Technical Analyst
Tango Therapeutics, Inc. [TNGX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Tango Therapeutics, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
1.50% $7.46
America/New_York / 17 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 796.12 mill |
| EPS: | -1.080 |
| P/E: | -6.91 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 106.72 mill |
| Avg Daily Volume: | 0.680 mill |
| RATING 2024-04-17 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -6.91 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.18x |
| Company: PE -6.91 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-6.34 (-184.92%) $-13.80 |
| Date: 2024-04-18 |
| Expected Trading Range (DAY) |
|---|
|
$ 6.88 - 8.04 ( +/- 7.75%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-20 | Third Rock Ventures Iv, L.p. | Sell | 162 500 | Common Stock |
| 2024-02-06 | Weber Barbara | Sell | 4 681 | Common Stock |
| 2024-02-07 | Weber Barbara | Sell | 4 457 | Common Stock |
| 2024-02-06 | Barry Douglas | Sell | 1 422 | Common Stock |
| 2024-02-07 | Barry Douglas | Sell | 1 354 | Common Stock |
| INSIDER POWER |
|---|
| 91.93 |
| Last 93 transactions |
| Buy: 16 052 308 | Sell: 885 960 |
Forecast:
16:00 - $7.46
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $7.46
Forecast 2: 16:00 - $7.46
Forecast 3: 16:00 - $7.46
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $7.46 (1.50% ) |
| Volume | 0.439 mill |
| Avg. Vol. | 0.680 mill |
| % of Avg. Vol | 64.53 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For TNGX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $12.15 | N/A | Active |
|---|
TNGX
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
Last 10 Buy Signals
Latest Press Releases
2024-04-01 16:48:00 - Press Release
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Boston--(business wire)--tango therapeutics, inc. (nasdaq: tngx), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that, effective april 1, 2024, the compensation committee of tango therapeutics' board of directors granted a non-qualified stock option to purchase 139,453 shares of its common stock and 23,698 restricted stock units (rsus) to a new employee under tango therapeutics' 2023 inducement pl.
2024-03-18 07:00:00 - Press Release
Tango Therapeutics Reports Fourth Quarter And Full Year 2023 Financial Results And Provides Business Highlights
Boston--(business wire)--tango therapeutics, inc. (nasdaq: tngx), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the fourth quarter and full year ended december 31, 2023, and provided business highlights. “in 2023, we made meaningful progress developing precision oncology treatments and now have four ongoing phase 1/2 clinical trials. these treatments have the potential to reach.
2024-03-06 07:00:00 - Press Release
Tango Therapeutics To Participate In Upcoming Investor Conferences
Boston--(business wire)--tango therapeutics, inc. (nasdaq: tngx), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that barbara weber, m.d., president and chief executive officer of tango therapeutics, is scheduled to participate in the following upcoming investor conferences in march. leerink partners 2024 global biopharma conference date: tuesday, march 12, 2024 time: 3:00 pm et location: miami, f.
2024-03-05 16:47:00 - Press Release
Tango Therapeutics To Highlight Preclinical Data On Precision Oncology Pipeline At The American Association For Cancer Research (aacr) Annual Meeting 2024
Boston, march 05, 2024 (globe newswire) -- tango therapeutics, inc. (nasdaq: tngx), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that one abstract has been selected for an oral minisymposium and seven abstracts have been accepted as poster presentations at the american association for cancer research (aacr) annual meeting 2024, taking place april 5-10, 2024, in san diego, california.
2024-01-31 07:00:00 - Press Release
Tango Therapeutics To Present At The Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
Boston, jan. 31, 2024 (globe newswire) -- tango therapeutics, inc. (nasdaq: tngx), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that barbara weber, m.d., president and chief executive officer of tango therapeutics, is scheduled to present at the guggenheim healthcare talks | 6th annual biotechnology conference on wednesday, february 7, 2024 at 11:30 am est.
Latest News
2024-03-18 09:10:25 - Zacks Investment Research
Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates
Tango Therapeutics, Inc. (TNGX) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.33 per share a year ago.
2024-01-31 07:00:00 - GlobeNewsWire
Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
BOSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference on Wednesday, February 7, 2024 at 11:30 AM EST.
2023-12-21 10:32:11 - Zacks Investment Research
3 Cancer-Focused Biotechs That Appear Promising Bets for 2024
With the spotlight on oncology-focused companies in the biotech sector in 2023, we discuss three stocks that have a promising oncology portfolio/pipeline for 2024.
2023-12-08 11:16:31 - Zacks Investment Research
Wall Street Analysts Predict an 110.53% Upside in Tango Therapeutics, Inc. (TNGX): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 110.5% in Tango Therapeutics, Inc. (TNGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
2023-10-23 18:26:00 - Seeking Alpha
Circling Bank On Tango Therapeutics
We are circling back on clinical stage developmental concern Tango Therapeutics, Inc. for the first time since November 2022. The company recently raised capital to fund all operations well into 2027, and a beneficial owner/director just added just over $2.4 million of new shares to their stake. An updated analysis on Tango Therapeutics follows in the paragraphs below.
2023-10-10 12:47:32 - Zacks Investment Research
Tango Therapeutics (TNGX) Rises 20% in a Month: Here's Why
The upside in Tango's (TNGX) shares can be attributed to the company's progress with its pipeline candidates. A recent acquisition offer for a biotech making similar drugs also bolstered this surge.
2023-10-09 11:53:07 - The Motley Fool
Why Shares of Tango Therapeutics Are Dropping Monday
Tango Therapeutics is a clinical-stage biotech. The company has five programs in its pipeline that are focused on fighting various cancers.
2023-10-09 10:31:58 - Zacks Investment Research
What Makes Tango Therapeutics, Inc. (TNGX) a Good Fit for 'Trend Investing'
Tango Therapeutics, Inc. (TNGX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
2023-09-14 17:55:00 - The Motley Fool
Why Shares of Tango Therapeutics Climbed This Week
Tango said it has $310.7 million in cash, enough to fund operations into 2026. The company has several early-stage trials.
2023-08-17 05:05:00 - The Motley Fool
Up 126% in 3 Days, Is Tango Therapeutics a Buy Right Now?
Tango Therapeutics just beefed up its cash reserves with a private stock sale. Tango's pipeline has a few early-stage programs that may become promising.